Annals of Hematology

, Volume 94, Issue 6, pp 969–973 | Cite as

Antibiotic treatment as sole management of Helicobacter pylori-negative gastric MALT lymphoma: a single center experience with prolonged follow-up

  • Markus RadererEmail author
  • Stefan Wöhrer
  • Barbara Kiesewetter
  • Werner Dolak
  • Heimo Lagler
  • Andrew Wotherspoon
  • Leonhard Muellauer
  • Andreas Chott
Original Article


Relatively little is known about the long-term outcome of patients with Helicobacter pylori (HP)-negative gastric lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) with antibiotic therapy as sole management. We have analyzed all patients with HP-negative gastric MALT lymphoma undergoing antibiotic therapy as sole management of their disease. HP negativity was defined as negative histology, breath test and serology, and response to treatment, survival and long-term outcome was assessed together with clinico-pathological characteristics including t(11; 18) (q21; q21) translocation. Out of 97 patients with gastric MALT lymphoma, 24 were HP-negative, and 13 (5 females and 8 males) underwent only antibiotic management for initial therapy. Eight had stage I and five were found to have stage II disease, with three patients suffering from an underlying autoimmune disease. Antibiotic therapy consisted of standard HP eradication regimens consisting of clarithromycin in all patients, along with metronidazole in seven and amoxicillin in six plus a proton-pump inhibitor. After a median follow-up of 95 months (42–, 181+), 12/13 patients are alive. Six patients with stage I disease achieved an objective response (five complete (CR) and one partial remission, 46 %), four had stable disease (lasting 11–27 months), and three progressed. All patients with stable disease received chemotherapy, but only one patient due to clear cut progression. One patient relapsed 23 months after initial CR, and achieved a second CR with antibiotics now lasting 87 months. These results indicate that a relevant percentage of patients with HP-negative gastric MALT lymphoma may benefit from antibiotic therapy and do not require additional oncological therapies. Our data suggest that the remissions seen in these patients might be durable as evidenced by prolonged follow-up in our series.


MALT lymphoma Helicobacter pylori Antibiotics 


Conflict of interest

The authors disclose no potential conflict of interest for this manuscript. All authors have analyzed the data, helped in drafting and writing the manuscript and have approved of the final version of the paper.


  1. 1.
    Swerdlow SH, Campo E, Harris NL et al (2008) The World Health Organization classification of tumours of haematopoietic and lymphoid tissues. WHO, LyonGoogle Scholar
  2. 2.
    Ruskone-Fourmestraux A, Fischbach W, Aleman BMP et al (2011) EGILS consensus report. Gastric extranodal marginal zone B-cell lymphoma of MALT. Gut 60:747–758CrossRefPubMedGoogle Scholar
  3. 3.
    Zucca E, Copie-Bergman C, Ricardi U et al (2013) Gastric marginal zone lymphoma of MALT-type: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 24(suppl 6):v144–v148CrossRefGoogle Scholar
  4. 4.
    Zullo A, Hassan C, Cristofari F et al (2010) Effects of Helicobacter pylori eradication on early stage gastric mucosa-associated lymphoid tissue lymphoma. Clin Gastroenterol Hepatol 8:105–110CrossRefPubMedGoogle Scholar
  5. 5.
    Steinbach G, Ford R, Glober G et al (1999) Antibiotic treatment of gastric lymphoma of mucosa-associated lymphoid tissue. An uncontrolled trial. Ann Intern Med 131:88–95CrossRefPubMedGoogle Scholar
  6. 6.
    Ruskone-Fourmestraux A, Lavergne A, Aegerter PH et al (2001) Predictive factors for regression of gastric MALT lymphoma after anti-Helicobacter pylori treatment. Gut 48:297–303CrossRefPubMedGoogle Scholar
  7. 7.
    Raderer M, Streubel B, Woehrer S et al (2006) Successful antibiotictreatment of Helicobacter pylori negative gastric mucosa associated lymphoid tissue lymphomas. Gut 55:616–618CrossRefPubMedCentralPubMedGoogle Scholar
  8. 8.
    Akamatsu T, Mochizuki T, Okiyama Y et al (2006) Comparison of localized gastric mucosa-associated lymphoid tissue (MALT) lymphoma with and without Helicobacter pylori infection. Helicobacter 11:86–95CrossRefPubMedGoogle Scholar
  9. 9.
    Nozaki K, Nomura S, Shimizu N et al (2006) Helicobacter pylori negative/API2-MALT1 translocation-negative low-grade MALT lymphoma. Gastric Cancer 9:229–234CrossRefPubMedGoogle Scholar
  10. 10.
    Dong G, Liu C, Ye H et al (2008) BCL10 nuclear expression and t(11;18)(q21;q21) indicate nonresponsiveness to Helicobacter pylori eradication of Chinese primary gastric MALT lymphoma. Int J Hematol 88:516–523CrossRefPubMedGoogle Scholar
  11. 11.
    Terai S, Iijima K, Kato K et al (2008) Long-term outcomes of gastric mucosa-associated lymphoid tissue lymphomas after Helicobacter pylori eradication therapy. Tohoku J Exp Med 214:79–87CrossRefPubMedGoogle Scholar
  12. 12.
    Nakamura T, Seto M, Tajika M et al (2008) Clinical features and prognosis of gastric MALT lymphoma with special reference to responsiveness to H. pylori eradication and API2-MALT1 status. Am J Gastroenterol 103:62–70CrossRefPubMedGoogle Scholar
  13. 13.
    Sumida T, Kitadai Y, Hiyama T et al (2009) Antibodies to Helicobacter pylori and CagA protein are associated with the response to antibacterial therapy in patients with H. pylori positive API2-MALT1-negative gastric MALT lymphoma. Cancer Sci 100:1075–1081CrossRefPubMedGoogle Scholar
  14. 14.
    Park HS, Kim YJ, Yang WI et al (2010) Treatment outcome of localized Helicobacter pylori-negative low-grade gastric MALT lymphoma. World J Gastroenterol 16:2158–2162CrossRefPubMedCentralPubMedGoogle Scholar
  15. 15.
    Nakamura S, Sugiyama T, Matsumoto T et al (2012) Long-term clinical outcome of gastric MALT lymphoma after eradication of Helicobacter pylori: a multicentre cohort follow-up study of 420 patients in Japan. Gut 61:507–513CrossRefPubMedGoogle Scholar
  16. 16.
    Choi YJ, Kim N, Paik JH et al (2013) Characteristics of Helicobacter pylori-positive and Helicobacter-pylori negative gastric mucosa-associated lymphoid tissue lymphoma and their influence on clinical outcome. Helicobacter 18:197–205CrossRefPubMedGoogle Scholar
  17. 17.
    Zullo A, Hassan C, Ridolda L et al (2013) Eradication therapy in Helicobacter pylori-negative, gastric low-grade mucosa-associated lymphoid tissue lymphoma patients. A systematic review. J CLin Gastroenterol 47:824–827CrossRefPubMedGoogle Scholar
  18. 18.
    Copie-Bergman C, Wotherspoon AC, Capella C et al (2013) GELA histological scoring system for post-treatment biopsies of patients with gastric MALT lymphoma is feasible and reliable in routine practice. Br J Haematol 160(1):47–52CrossRefPubMedGoogle Scholar
  19. 19.
    Akamatsu T, Mochizuki T, Okiyama Y, Matsumoto A, Miyabayashi H, Ota H (2006) Comparison of localized gastric mucosa-associated lymphoid tissue (MALT) lymphoma with and without Helicobacter pylori infection. Helicobacter 11:86–95CrossRefPubMedGoogle Scholar
  20. 20.
    Chung SJ, Kim JS, Kim H, Kim SG, Kim CW, Jung HC, Song IS (2009) Long-term clinical outcome of Helicobacter pylori-negative gastric mucosa-associated lymphoid tissue lymphoma is comparable to that of H. pylori-positive lymphoma. J Clin Gastroenterol 43:3CrossRefGoogle Scholar
  21. 21.
    Morgner A, Lehn N, Andersen LP, Thiede C, Bennedsen M, Trebesius K, Neubauer B, Neubauer A, Stolte M, Bayerdörffer E (2000) Helicobacter heilmannii-associated primary gastric low-grade MALT lymphoma: complete remission after curing the infection. Gastroenterology 118(5):821–828CrossRefPubMedGoogle Scholar
  22. 22.
    Govi S, Dognini GP, Licata G et al (2010) Six-month oral clarithromycin regimen is safe and active in extranodal marginal zone B-cell lymphomas: final results of a single-centre phase II trial. Br J Haematol 150(2):226–229PubMedGoogle Scholar
  23. 23.
    Kiesewetter B, Raderer M (2013) Antibiotic therapy in nongastrointestinal MALT lymphoma: a review of the literature. Blood 122(8):1350–1357CrossRefPubMedGoogle Scholar
  24. 24.
    Ye H, Liu H, Raderer M et al (2003) High incidence of t(11;18)(q21;q21) in Helicobacter pylori-negative gastric MALT lymphoma. Blood 101(7):2547–2580CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • Markus Raderer
    • 1
    • 7
    Email author
  • Stefan Wöhrer
    • 1
    • 6
  • Barbara Kiesewetter
    • 1
  • Werner Dolak
    • 2
  • Heimo Lagler
    • 1
  • Andrew Wotherspoon
    • 3
  • Leonhard Muellauer
    • 4
  • Andreas Chott
    • 5
  1. 1.Department of Internal Medicine IMedical University ViennaViennaAustria
  2. 2.Department of Internal Medicine IIIMedical University ViennaViennaAustria
  3. 3.Department of HistopathologyRoyal Marsden HospitalLondonUK
  4. 4.Departments of Internal Medicine and PathologyMedical University ViennaViennaAustria
  5. 5.Departments of Internal Medicine and PathologyWilheminenspitalViennaAustria
  6. 6.Krankenhaus Wiener NeustadtViennaAustria
  7. 7.Department of Internal Medicine I, Division of OncologyMedical UniversityViennaAustria

Personalised recommendations